IL267968B - Selective hdac6 inhibitors, a method for their preparation and application - Google Patents
Selective hdac6 inhibitors, a method for their preparation and applicationInfo
- Publication number
- IL267968B IL267968B IL267968A IL26796819A IL267968B IL 267968 B IL267968 B IL 267968B IL 267968 A IL267968 A IL 267968A IL 26796819 A IL26796819 A IL 26796819A IL 267968 B IL267968 B IL 267968B
- Authority
- IL
- Israel
- Prior art keywords
- preparation
- application
- selective inhibitors
- hdac6 selective
- hdac6
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710017287 | 2017-01-10 | ||
| PCT/CN2018/072088 WO2018130155A1 (zh) | 2017-01-10 | 2018-01-10 | Hdac6选择性抑制剂及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL267968A IL267968A (en) | 2019-10-31 |
| IL267968B true IL267968B (en) | 2022-06-01 |
Family
ID=62839715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267968A IL267968B (en) | 2017-01-10 | 2019-07-10 | Selective hdac6 inhibitors, a method for their preparation and application |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10745389B2 (enExample) |
| EP (1) | EP3569592B8 (enExample) |
| JP (1) | JP7237010B2 (enExample) |
| KR (1) | KR102549606B1 (enExample) |
| CN (1) | CN110382463B (enExample) |
| AU (1) | AU2018208160B2 (enExample) |
| ES (1) | ES2927352T3 (enExample) |
| IL (1) | IL267968B (enExample) |
| MX (1) | MX394624B (enExample) |
| SA (1) | SA519402090B1 (enExample) |
| SG (1) | SG11201906361YA (enExample) |
| WO (1) | WO2018130155A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020007329A1 (zh) * | 2018-07-04 | 2020-01-09 | 基石药业（苏州）有限公司 | Hdac6选择性抑制剂的晶型及其应用 |
| CN115443329A (zh) | 2019-06-27 | 2022-12-06 | 乔治华盛顿大学国会特许非营利公司 | Hdac6激活的巨噬细胞、其组合物及用途 |
| WO2021110121A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Hdac6选择性抑制剂及其组合疗法 |
| KR20220119653A (ko) | 2019-12-20 | 2022-08-30 | 테나야 테라퓨틱스, 인코포레이티드 | 플루오로알킬-옥사디아졸 및 이의 용도 |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| WO2024123700A1 (en) * | 2022-12-05 | 2024-06-13 | The General Hospital Corporation | Histone deacetylase inhibitors |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005517007A (ja) * | 2002-02-07 | 2005-06-09 | アクシス・ファーマスーティカルズ | ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート |
| CN101641338A (zh) * | 2006-09-11 | 2010-02-03 | 柯瑞斯公司 | 作为抗增殖制剂的多功能小分子 |
| KR20110038159A (ko) | 2008-07-28 | 2011-04-13 | 길리애드 사이언시즈, 인코포레이티드 | 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물 |
| WO2011106632A1 (en) | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| NZ610225A (en) | 2010-11-16 | 2015-08-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| US8404738B2 (en) | 2011-01-21 | 2013-03-26 | Hoffmann-La Roche Inc. | 4-amino-N-hydroxy-benzamides for the treatment of cancer |
| EP2826769A1 (en) * | 2013-07-18 | 2015-01-21 | Institut de Recherche pour le Développement ( IRD) | Compounds for the treatment and/or prevention of parasitic diseases and method of production thereof |
| CA2933907A1 (en) * | 2013-12-23 | 2015-07-02 | The Trustees Of Columbia University In The City Of New York | Selective hdac6 inhibitors |
| US9464073B2 (en) * | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
-
2018
- 2018-01-10 EP EP18739134.7A patent/EP3569592B8/en active Active
- 2018-01-10 SG SG11201906361YA patent/SG11201906361YA/en unknown
- 2018-01-10 MX MX2019008181A patent/MX394624B/es unknown
- 2018-01-10 US US16/476,660 patent/US10745389B2/en active Active
- 2018-01-10 AU AU2018208160A patent/AU2018208160B2/en active Active
- 2018-01-10 ES ES18739134T patent/ES2927352T3/es active Active
- 2018-01-10 JP JP2019557669A patent/JP7237010B2/ja active Active
- 2018-01-10 WO PCT/CN2018/072088 patent/WO2018130155A1/zh not_active Ceased
- 2018-01-10 KR KR1020197022672A patent/KR102549606B1/ko active Active
- 2018-01-10 CN CN201880006463.5A patent/CN110382463B/zh active Active
-
2019
- 2019-07-09 SA SA519402090A patent/SA519402090B1/ar unknown
- 2019-07-10 IL IL267968A patent/IL267968B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3569592B1 (en) | 2022-08-24 |
| US20190375735A1 (en) | 2019-12-12 |
| EP3569592B8 (en) | 2022-11-30 |
| IL267968A (en) | 2019-10-31 |
| RU2019124962A (ru) | 2021-02-15 |
| CA3049834A1 (en) | 2018-07-19 |
| JP7237010B2 (ja) | 2023-03-10 |
| JP2020505440A (ja) | 2020-02-20 |
| ES2927352T8 (es) | 2022-11-18 |
| EP3569592A4 (en) | 2020-08-12 |
| KR102549606B1 (ko) | 2023-06-29 |
| CN110382463B (zh) | 2022-11-04 |
| SA519402090B1 (ar) | 2022-05-30 |
| KR20190103286A (ko) | 2019-09-04 |
| RU2019124962A3 (enExample) | 2021-05-11 |
| SG11201906361YA (en) | 2019-08-27 |
| AU2018208160A1 (en) | 2019-08-15 |
| CN110382463A (zh) | 2019-10-25 |
| WO2018130155A1 (zh) | 2018-07-19 |
| MX394624B (es) | 2025-03-24 |
| US10745389B2 (en) | 2020-08-18 |
| ES2927352T3 (es) | 2022-11-04 |
| EP3569592A1 (en) | 2019-11-20 |
| MX2019008181A (es) | 2019-12-09 |
| AU2018208160B2 (en) | 2021-03-04 |
| BR112019014152A2 (pt) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275055A (en) | Tertiary antibody, method for its preparation and use | |
| IL268955B (en) | Selective hdac6 inhibitors | |
| IL278036A (en) | 1HPK inhibitors, method of preparation and administration | |
| EP3694181A4 (en) | SESSION ESTABLISHMENT PROCESS, DEVICE AND SYSTEM | |
| GB201803106D0 (en) | Device, system and method | |
| PL3486242T3 (pl) | Pochodna oksopikolinamidu, sposób jej wytwarzania i zastosowanie farmaceutyczne | |
| EP3381919A4 (en) | Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof | |
| EP3569592B8 (en) | Hdac6 selective inhibitors, preparation method therefor, and application thereof | |
| SG11201703106PA (en) | Device, method, and program | |
| EP3244372A4 (en) | Effect generating device, effect generating method, and program | |
| GB201608192D0 (en) | Method, array and use thereof | |
| GB201516801D0 (en) | Method, array and use thereof | |
| GB201805095D0 (en) | Compostion, method and use | |
| EP3316184A4 (en) | Program generating device, program generating method, and generating program | |
| GB2564511B (en) | Composition, method and use | |
| SG11202007554TA (en) | Dioxazoline compound, preparation method therefor, and uses thereof | |
| EP3352467A4 (en) | RECEIVING DEVICE, RECEIVING METHOD AND PROGRAM | |
| EP3296985A4 (en) | Image-processing device, image-processing method, and program | |
| SG11201802300YA (en) | Device, method, and program | |
| GB202002352D0 (en) | Hygiene compliance method, use and system | |
| EP3297171A4 (en) | Decoding device, decoding method, and program | |
| SG11201708833PA (en) | Device, method, and program | |
| EP3372152A4 (en) | Assessment device, assessment method, and assessment program | |
| GB201805016D0 (en) | Composition, method and use | |
| ZA201800493B (en) | Deuterated thienopiperidine derivatives, manufacturing method, and application thereof |